VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Conditions

• Head and Neck Carcinoma
• Adenoid Cystic Carcinoma
• Lung Cancer
• Non-Small Cell Lung Cancer
• Pancreatic Cancer
• Mesothelioma
• Esophageal Cancer
• Any Solid Tumors Progressed After a Prior Immunotherapy
• Head and Neck Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma HNSCC
• Salivary Gland Carcinomas
• Head and Neck Cancers - Salivary Gland
• Head and Neck Cancers - Nasopharyngeal
• Head and Neck Cancers - Throat
• Small Cell Lung Cancer ( SCLC )
• Lung Cancer (Locally Advanced or Metastatic)
• Head and Neck Cancers - Tonsils
• Head and Neck Cancers Hypopharynx
• Head and Neck Cancers Larynx
• Head and Neck Cancers Lip
• Head and Neck Cancers Nasopharynx
• Head and Neck Cancers Oral Cavity
• Head and Neck Cancers
• Head and Neck Cancers Oropharynx
• Head and Neck Cancers Trachea

Interventions

• DRUG: VMD-928 100 mg Tablet
• DRUG: VMD-928 Tablet and Pembrolizumab (200 mg)

Sponsor

VM Oncology, LLC